Maxim starts Cero Therapeutics at Buy, positive on its novel t-cell therapy

Maxim initiated coverage of Cero Therapeutics (CERO) with a Buy rating and $3 price target The company’s T-cell therapy approach leverages the highly controlled, natural distressed/apoptotic cell elimination functions of the immune system, with limited off-targeting, and the the CER-T platform could have success where traditional CAR-T approaches have faced challenges, the analyst tells investors in a research note. Maxim adds that Cero’s lead indication is acute myeloid leukemia, AML, where Phase 1 study is expected to dose first patients soon, while an IND cleared for a Phase 1 in advanced solid tumors should start after the AML trial is underway.